Oncology ESMO 2024 - Israel (Izzy) Lowy ESMO 2024, which followed hot on the heels of this year’s World Conference on Lung Cancer, was abuzz with data around PD-1 inhibitors, LAG-3 inhibitors, and the possibilities for using exis
News UK MHRA green lights AbbVie’s ELAHERE for ovarian cancer AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibo
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face